Department of Experimental Medicine, Tor Vergata Oncoscience Research (TOR), University of Rome Tor Vergata, 00133 Rome, Italy.
Department of Surgical Sciences, Division of Urology, University of Rome Tor Vergata, 00133 Rome, Italy.
Int J Mol Sci. 2023 Mar 30;24(7):6519. doi: 10.3390/ijms24076519.
Prostate cancer is the most frequently diagnosed cancer and the fifth leading cause of cancer death among men in 2020. The clinical decision making for prostate cancer patients is based on the stratification of the patients according to both clinical and pathological parameters such as Gleason score and prostate-specific antigen levels. However, these tools still do not adequately predict patient outcome. The aim of this study was to investigate whether ZNF750 could have a role in better stratifying patients, identifying those with a higher risk of metastasis and with the poorest prognosis. The data reported here revealed that ZNF750 protein levels are reduced in human prostate cancer samples, and this reduction is even higher in metastatic samples. Interestingly, nuclear positivity is significantly reduced in patients with metastatic prostate cancer, regardless of both Gleason score and grade group. More importantly, the bioinformatics analysis indicates that ZNF750 expression is positively correlated with better prognosis. Overall, our findings suggest that nuclear expression of ZNF750 may be a reliable prognostic biomarker for metastatic prostate cancer, which lays the foundation for the development of new biological therapies.
前列腺癌是 2020 年男性中最常见的癌症，也是癌症死亡的第五大主要原因。前列腺癌患者的临床决策是基于对患者进行临床和病理参数（如 Gleason 评分和前列腺特异性抗原水平）分层的基础上做出的。然而，这些工具仍然不能充分预测患者的预后。本研究旨在探讨 ZNF750 是否可以在更好地分层患者方面发挥作用，以识别那些具有更高转移风险和预后最差的患者。这里报告的数据显示，ZNF750 蛋白水平在人前列腺癌样本中降低，在转移性样本中降低更为明显。有趣的是，核阳性在转移性前列腺癌患者中显著减少，无论 Gleason 评分和分级组如何。更重要的是，生物信息学分析表明，ZNF750 的表达与更好的预后呈正相关。总的来说，我们的研究结果表明，ZNF750 的核表达可能是转移性前列腺癌的可靠预后生物标志物，为新的生物治疗方法的发展奠定了基础。
